CN101610758A - 含有三取代甘油化合物的口服剂型 - Google Patents

含有三取代甘油化合物的口服剂型 Download PDF

Info

Publication number
CN101610758A
CN101610758A CNA2007800417728A CN200780041772A CN101610758A CN 101610758 A CN101610758 A CN 101610758A CN A2007800417728 A CNA2007800417728 A CN A2007800417728A CN 200780041772 A CN200780041772 A CN 200780041772A CN 101610758 A CN101610758 A CN 101610758A
Authority
CN
China
Prior art keywords
dosage forms
solid dosage
pharmaceutical solid
dosage form
tri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800417728A
Other languages
English (en)
Chinese (zh)
Inventor
沃尔夫冈·里克特
卢茨·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphaptose GmbH
Original Assignee
Alphaptose GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphaptose GmbH filed Critical Alphaptose GmbH
Publication of CN101610758A publication Critical patent/CN101610758A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800417728A 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型 Pending CN101610758A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85815706P 2006-11-10 2006-11-10
US60/858,157 2006-11-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310689824.XA Division CN103816127A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型

Publications (1)

Publication Number Publication Date
CN101610758A true CN101610758A (zh) 2009-12-23

Family

ID=39092201

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800417728A Pending CN101610758A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型
CN201310689824.XA Pending CN103816127A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310689824.XA Pending CN103816127A (zh) 2006-11-10 2007-11-09 含有三取代甘油化合物的口服剂型

Country Status (11)

Country Link
US (2) US20110110984A1 (https=)
EP (1) EP2091520B1 (https=)
JP (1) JP5352466B2 (https=)
CN (2) CN101610758A (https=)
AT (1) ATE546133T1 (https=)
AU (1) AU2007316588B2 (https=)
CA (1) CA2668919C (https=)
DK (1) DK2091520T3 (https=)
ES (1) ES2382756T3 (https=)
RU (1) RU2009121838A (https=)
WO (1) WO2008055996A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616676B (zh) * 2006-12-20 2015-09-09 汉堡-艾本德大学医学中心 三取代的甘油化合物用于治疗恶性血液病的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
EP1952803A1 (en) * 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2619686C2 (de) 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
DE3530767A1 (de) 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
DE4000084A1 (de) 1990-01-03 1991-07-04 Medmark Pharma Gmbh Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts)
WO1999030690A1 (en) * 1997-12-15 1999-06-24 Axia Therapeutics, Inc. Oral delivery formulation
DE19822509A1 (de) * 1998-05-19 1999-11-25 Medmark Pharma Gmbh Edelfosin zur Behandlung von Hirntumoren
DE19829448A1 (de) 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
JP2002532553A (ja) * 1998-12-21 2002-10-02 インケイサ．ソシエダ アノニマ 有害な胃腸副作用を引き起こさない有力な抗炎症剤としてのエーテルリゾリン脂質の使用
WO2003063831A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616676B (zh) * 2006-12-20 2015-09-09 汉堡-艾本德大学医学中心 三取代的甘油化合物用于治疗恶性血液病的应用

Also Published As

Publication number Publication date
CA2668919A1 (en) 2008-05-15
US20110110984A1 (en) 2011-05-12
US20170157150A1 (en) 2017-06-08
ES2382756T3 (es) 2012-06-13
JP5352466B2 (ja) 2013-11-27
CN103816127A (zh) 2014-05-28
CA2668919C (en) 2015-11-03
JP2010509293A (ja) 2010-03-25
WO2008055996A1 (en) 2008-05-15
DK2091520T3 (da) 2012-06-18
RU2009121838A (ru) 2010-12-20
AU2007316588A1 (en) 2008-05-15
EP2091520A1 (en) 2009-08-26
AU2007316588B2 (en) 2013-11-21
EP2091520B1 (en) 2012-02-22
ATE546133T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
JP3954117B2 (ja) 有効物質を徐々に遊離する、トラマドール塩含有薬剤
JP7269227B2 (ja) ニラパリブ処方物
EP2468261A1 (en) Formulation of lacosamide
CN102665693A (zh) 利福昔明固体分散体
RS64139B1 (sr) Kompozicije za ileo-jejunalnu isporuku leka
CN101903016A (zh) 氢溴酸安非他酮以及治疗的应用
KR102598782B1 (ko) 알펠리십을 포함하는 제약 조성물
KR20200088382A (ko) 방출 제어 제제
KR20180125573A (ko) 유효 성분의 화학적 안정성이 뛰어난 필름 코팅정
US20170157150A1 (en) Oral dosage form comprising tri-substituted glycerol compounds
JP3833314B2 (ja) 発泡性組成物およびその製造方法
US20140178470A1 (en) Dispersible tablet
WO2023284724A1 (zh) 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用
KR20130023127A (ko) 프레가발린을 포함하는 서방성 제제
WO2017029225A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
JP2014101332A (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
JP2014530828A (ja) 有機化合物におけるまたは有機化合物に関連する改善
TW200914017A (en) Stable pharmaceutical composition of a water-soluble vinorelbine salt
WO2014167439A1 (en) Modified release pharmaceutical compositions of topiramate or salts thereof
JP2016530329A (ja) ペレット包含錠剤
HK40084155A (en) Pharmaceutical compositions comprising alpelisib
CN121925252A (zh) 用于口服给药的含有卡巴他赛和脂质的组合物
WO2024211882A1 (en) Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CA3200729A1 (en) Pharmaceutical composition comprising meloxicam
HK1228298B (en) Pharmaceutical compositions comprising an s1p modulator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091223